EN DE
Watch DR.AGARWALS EYE HOSPITAL LTD.-$ for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of DR.AGARWALS EYE HOSPITAL LTD.-$ stock ₹2,708, price ₹5,813, that is 53.4% below the price, quality 54 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE934C01018

DA DR.AGARWALS EYE HOSPITAL LTD.-$ logo Broad data Nov 14, 2026

DR.AGARWALS EYE HOSPITAL LTD.-$

DRAGARWQ · BSE

Far too expensive (fair value 53% below the price), but solid company and rising price: meets 2 of 3 rules.

Follow free in the weekly email
Rising price (uptrend) 
Solidly profitable · 15.3% net margin (TTM) 
Low debt 
Generates free cash flow 
0.1% dividend yield · Well covered
Wide moat 73/100
Broad data 
Last quarter vs. a year ago: revenue +22%, profit +32%. 
Quality 54/100 
Expensive Growth (revenue 5y +27.5 %/yr in INR) 
Mixed vs. peers (6/14) 
Fair value ₹2,708 · Strongly overvalued 
⚠ Small free float
Watch DR.AGARWALS EYE HOSPITAL LTD.-$ for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹6,972 ₹387.06 Fair Value ₹2,708 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range ₹387.06 – ₹6,972 · fair‑value band ₹1,385 – ₹3,989 · the ₹5,813 price screens above the ₹2,708 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow DR.AGARWALS EYE HOSPITAL LTD.-$ in your weekly email

Every Wednesday you see whether DR.AGARWALS EYE HOSPITAL LTD.-$ is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Dr. Agarwal's Eye Hospital Limited engages in the provision of eye care and related services in India, Ghana, Uganda, Kenya, Madagascar, Tanzania, Rwanda, Zambia, Mozambique, and Mauritius.

Show moreShow less

The company, through its hospitals, offers services in the areas of cataract, glaucoma, laser correction, cornea and refractive, retina, squint, keratitis, diabetic retinopathy, retinal detachment, nystagmus, ptosis, conjunctivitis, retinopathy prematurity, macular hole and edema, cornea transplantation, behcets, computer vision syndrome, hypertensive retinopathy, black fungus, traumatic cataract, keratoconus, uveitis, pterygium, blepharitis, posterior subcapsular cataract, rosette cataract, and congenital glaucoma.

Dr. Agarwal's Eye Hospital Limited was founded in 1957 and is based in Chennai, India. Dr. Agarwal's Eye Hospital Limited operates as a subsidiary of Dr. Agarwal's Health Care Limited.

Stock analysis

DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ) currently trades at ₹5,813, while our model-based Fair Value estimate is ₹2,708, 53% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹4,073 per share, and 1 of the 26 models we run sit above the ₹5,813 price.

Bear case: the Asset-Based group reads lowest at ₹441.66, and 25 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: ₹1,385 (bear) to ₹3,989 (bull), the price of ₹5,813 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

DR.AGARWALS EYE HOSPITAL LTD.-$ reported revenue of ₹4.7B in FY2026 versus ₹2.0B in FY2022, a compound +23.7%/yr. Reported net income was ₹701M in FY2026, compounding +30.6%/yr from FY2022.

Key figures

Market cap ₹28.1B (≈ $301M) Small · P/E ratio 36.6 · P/S ratio 5.65 · EPS (TTM) ₹158.78 · Dividend yield 0.1% · Net margin 15.3% · Return on equity 25.2% · Return on assets (EBIT) 13.1% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 73 out of 100 (medium confidence).

What moves the price

The share trades about 5% below its 52-week high and 30% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −53%, DRAGARWQ screens richer than that median.

Fair Value models

Bear ₹1,385 Fair Value ₹2,708 Bull ₹3,989
Price ₹5,813 · Downside -53.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹96.47 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ₹937.28 ₹1,364 ₹2,407 78
Growth DCF ₹883.21 ₹1,407 ₹2,232 77
EPV ₹964.52 ₹1,071 ₹1,154 74
All 26 models by family
DCF Models
FCF DCF ₹937.28 ₹1,364 ₹2,407 78
Owner Earnings ₹504.66 ₹1,018 ₹1,845 73
5Y Revenue Exit ₹1,385 ₹2,708 ₹5,289 68
5Y EBITDA Exit ₹1,996 ₹4,025 ₹7,742 71
5Y P/E Exit ₹1,601 ₹3,475 ₹5,883 68
10Y Revenue Exit ₹1,100 ₹2,334 ₹3,794 64
10Y EBITDA Exit ₹1,469 ₹3,203 ₹6,386 64
10Y P/E Exit ₹1,259 ₹2,641 ₹4,998 60
Earnings-Based
Graham-Dodd ₹986.34 ₹6,879 ₹9,653 63
Lynch FV ₹2,070 ₹2,957 ₹3,844 61
PEG = 1.0 ₹2,070 ₹2,957 ₹3,844 57
EPV ₹964.52 ₹1,071 ₹1,154 74
Dividend Discount
Gordon GGM ₹37.22 ₹56.65 ₹68.81 69
DDM Multi-Stage ₹37.22 ₹56.20 ₹61.36 67
Multiples
P/E Multiple ₹2,393 ₹3,191 ₹3,989 63
P/S Multiple ₹1,849 ₹2,466 ₹3,082 58
P/B Multiple ₹2,201 ₹2,934 ₹3,668 55
EV/EBIT ₹2,446 ₹3,313 ₹4,180 66
EV/EBITDA ₹2,978 ₹4,023 ₹5,067 67
EV/Revenue ₹1,701 ₹2,497 ₹3,292 53
Asset-Based
NCAV (Graham) ₹329.60 ₹441.66 ₹659.20 54
Growth DCF
Growth DCF ₹883.21 ₹1,407 ₹2,232 77
Rev-Margin DCF ₹1,385 ₹2,873 ₹5,093 69
Economic Profit
Residual Income ₹673.52 ₹872.08 ₹1,376 74
ROIC Compounder ₹1,066 ₹1,347 ₹1,676 72
Growth Earnings
Growth-Adj P/E ₹2,851 ₹4,073 ₹5,295 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 54/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 65
How much profit the company makes from its sales and capital
Quality Growth 57
Are margins and returns getting better?
Cashflow 63
Do the profits arrive as real cash?
Financial strength 62
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 88
How calm the share price moves, does not count
Price momentum 54
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 68
Distance to the 52-week high, does not count
New shares 63
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+18.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.5%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.7%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+29.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+29.3%
Dividend (yield on the price)0.1%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 21%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+46.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +40.7% a year for the price.

DRAGARWQ screens overvalued: fair value 53% below the price. Compare with HCA Healthcare, Inc →

Compare DR.AGARWALS EYE HOSPITAL LTD.-$ with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 248 stocks

Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 54 · Below median
Fair Value upside −53.4% · Bottom 25%
Profitability
Return on equity (12 months) 25.2% · Top 25%
Return on assets 9.2% · Top 25%
Net margin (12 months) 15.3% · Top 25%
Operating margin (12 months) 22.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 22.3% · Top 25%
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.19× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 36.6× · Priciest 25%
P/B 8.11× · Priciest 25%
P/S (12 months) 5.65× · Priciest 25%
Price / free cash flow (fiscal year) 60.1× · Priciest 25%
EV/EBITDA 18.4× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 36
FUTURE (revenue growth)100 · sector 33
PAST (return on equity)100 · sector 32
HEALTH (low debt)90 · sector 90
DIVIDEND (yield)2 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

DR.AGARWALS EYE HOSPITAL LTD.-$: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "DR.AGARWALS EYE HOSPITAL LTD.-$ Fair Value". https://www.fairvalue-calculator.com/stock/DRAGARWQ

Frequently asked questions

Is DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of ₹2,708 versus a price of ₹5,813, about 53% lower (overvalued).
What is the fair value of DRAGARWQ?
Our model-based fair value for DR.AGARWALS EYE HOSPITAL LTD.-$ is ₹2,708 (as of Nov 14, 2026), built from audited fundamentals. The current price: ₹5,813.
What is the quality score of DRAGARWQ?
DR.AGARWALS EYE HOSPITAL LTD.-$ has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
Our model-based price target is the fair value of ₹2,708 (as of Nov 14, 2026) from 26 valuation models. Cautious scenario ₹1,385, optimistic scenario ₹3,989. It is a calculation from audited fundamentals, not an analyst target.
What is the DR.AGARWALS EYE HOSPITAL LTD.-$ stock forecast for 2026?
Our models put fair value at ₹2,708, about 53% lower versus a price of ₹5,813 (overvalued). Cautious scenario ₹1,385, optimistic scenario ₹3,989. The calculation is refreshed regularly with new filings.
What is the revenue of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
DR.AGARWALS EYE HOSPITAL LTD.-$ reported trailing-twelve-month revenue of about ₹5.0B (latest available figure, as of Nov 14, 2026).
Does DR.AGARWALS EYE HOSPITAL LTD.-$ pay a dividend?
DR.AGARWALS EYE HOSPITAL LTD.-$ currently shows a dividend yield of 0.12% relative to its recent price (as of Nov 14, 2026).
How much is the dividend of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ) and when is the ex-dividend date?
DR.AGARWALS EYE HOSPITAL LTD.-$ pays a dividend of ₹7.00 per share a year, a dividend yield of 0.1%. The last ex-dividend date was Sep 2, 2026. A dividend has been paid every year since 2022. The payout ratio is 4.4% of earnings. Free cash flow covers the dividend 13.82 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
For today's price to be fair in a discounted-cash-flow model, DR.AGARWALS EYE HOSPITAL LTD.-$ would have to grow free cash flow by 46.5 % per year for five years (discount rate 15.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 27.5 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of DRAGARWQ use?
Our models discount DR.AGARWALS EYE HOSPITAL LTD.-$ at 15.4 %: a base by market capitalisation (micro), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DR.AGARWALS EYE HOSPITAL LTD.-$ that is +46.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (15.4 %) and the same formula as our fair value.
How much growth has DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ) delivered so far?
Over the past 5 years revenue at DR.AGARWALS EYE HOSPITAL LTD.-$ grew 27.5 % a year. The price currently implies free-cash-flow growth of +46.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into DR.AGARWALS EYE HOSPITAL LTD.-$ (+46.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
The free-cash-flow yield on the price is 1.66 %: that much free cash flow DR.AGARWALS EYE HOSPITAL LTD.-$ produces per unit of market value. When it exceeds the discount rate of our models (15.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DR.AGARWALS EYE HOSPITAL LTD.-$ it is ₹2,708 per share (as of Nov 14, 2026), against a price of ₹5,813. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is DR.AGARWALS EYE HOSPITAL LTD.-$ stock overvalued or undervalued in 2026?
As of Nov 14, 2026, DRAGARWQ trades above its calculated fair value: price ₹5,813, fair value ₹2,708, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DRAGARWQ?
No. The price is what the market pays today (₹5,813); the fair value is what the company's own numbers justify (₹2,708). For DR.AGARWALS EYE HOSPITAL LTD.-$ the two are ₹3,104 per share apart. That gap is exactly why we show both numbers side by side.
How much is DR.AGARWALS EYE HOSPITAL LTD.-$ worth?
The market values DR.AGARWALS EYE HOSPITAL LTD.-$ at about ₹28.1B (market capitalisation, as of Nov 14, 2026). Per share that is ₹5,813; our models calculate a fair value of ₹2,708 per share.
What do the bullish and bearish scenarios say about DRAGARWQ?
Our models span a range for DR.AGARWALS EYE HOSPITAL LTD.-$: cautious scenario ₹1,385, base ₹2,708, optimistic ₹3,989 per share (as of Nov 14, 2026, price ₹5,813). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DRAGARWQ?
DR.AGARWALS EYE HOSPITAL LTD.-$ trades at a price-to-earnings ratio of 36.6 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹2,708 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2019 to 2026), reported earnings: 14.3. Other multiples: P/B 8.1, P/S 5.7, EV/EBITDA 18.4.
How solid is the balance sheet of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
Balance-sheet figures for DR.AGARWALS EYE HOSPITAL LTD.-$ (as of Nov 14, 2026): return on equity 25.2%, debt of 0.19 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is DRAGARWQ from its 52-week high?
DR.AGARWALS EYE HOSPITAL LTD.-$ trades at ₹5,813, about 5% below its 52-week high of ₹6,098 and 30% above the low of ₹4,475 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of ₹2,708 is for.
Which stocks are comparable to DR.AGARWALS EYE HOSPITAL LTD.-$?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DR.AGARWALS EYE HOSPITAL LTD.-$ stock attractive at the current price?
The data as of Nov 14, 2026: price ₹5,813, calculated fair value ₹2,708 (−53%), Quality Score 54/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DRAGARWQ calculated?
We run DR.AGARWALS EYE HOSPITAL LTD.-$ through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹2,708 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3% above its aggregate fair value. DR.AGARWALS EYE HOSPITAL LTD.-$ itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
The closing price on Nov 17, 2026 was ₹5,813. Our model-based fair value is ₹2,708, about 53% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DR.AGARWALS EYE HOSPITAL LTD.-$ right now?
The price sits above even our optimistic bull case (₹3,989). The favourable scenario is already priced in. The model range is unusually wide (₹1,385 to ₹3,989). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of DR.AGARWALS EYE HOSPITAL LTD.-$

How large is the market capitalisation of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
The market capitalisation of DR.AGARWALS EYE HOSPITAL LTD.-$ is ₹28.1B (≈ $301M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
The price-to-sales ratio of DR.AGARWALS EYE HOSPITAL LTD.-$ is 5.65 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
Earnings per share at DR.AGARWALS EYE HOSPITAL LTD.-$ are ₹158.78 (price ÷ EPS = P/E 36.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
The dividend yield of DR.AGARWALS EYE HOSPITAL LTD.-$ is 0.1% (payout 4.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
The net margin of DR.AGARWALS EYE HOSPITAL LTD.-$ is 15.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
The return on equity (ROE) of DR.AGARWALS EYE HOSPITAL LTD.-$ is 25.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
On an EBIT basis the return on assets of DR.AGARWALS EYE HOSPITAL LTD.-$ is 13.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
The operating margin of DR.AGARWALS EYE HOSPITAL LTD.-$ is 22.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
Revenue at DR.AGARWALS EYE HOSPITAL LTD.-$ is growing 22.3% versus a year earlier (3y avg +20.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ)?
Earnings per share at DR.AGARWALS EYE HOSPITAL LTD.-$ are growing 31.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does DR.AGARWALS EYE HOSPITAL LTD.-$ (DRAGARWQ) carry?
The net debt of DR.AGARWALS EYE HOSPITAL LTD.-$ is ₹752M (fiscal year 2026, ≈ 1.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch DR.AGARWALS EYE HOSPITAL LTD.-$ in the live analysis

One click puts DR.AGARWALS EYE HOSPITAL LTD.-$ on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.